Scholarlink

Objective <p>To assess the safety and efficacy of Rezūm therapy in small versus large prostates through a four-year follow-up.</p> Patients and methods <p>One-hundred seventy patients who underwent Rezūm therapy were retrospectively included and divided into 2 equal groups, small (˂ 80gm) and large prostate groups (80-120 gm). Both groups were assessed preoperatively and at 3, 12, 24, 36, and 48 months post-procedure for operative time, number of vapor injection, catheterization time, hospital stay and post-procedure: prostatic size, prostate-specific antigen (PSA), post-void residual (PVR), maximum urinary flow<!--Query ID="Q1" Text="Please check and confirm that the authors and their respective affiliations have been correctly identified and amend if necessary." Resolved="yes"--> rate (Qmax), International Prostate Symptom Score (IPSS), quality of life (QoL), International Index of Erectile Function (IIEF) and complications.</p> Results <p>The number of vapor injections was significantly higher in the large prostate group compared to the small prostate group (<i>p</i> &lt; 0.001). Operative time and catheter duration were significantly longer in the large prostate group (<i>p</i> &lt; 0.001), while hospital stay was similar between groups (<i>p</i> = 0.407). At 48 months post-Rezūm, both groups demonstrated statistically significant improvement in all measured outcomes (Qmax, IPSS, PVR, QoL, PSA, IIEF, and prostate size) (<i>p</i> &lt; 0.05). Regarding postoperative complications, there were no significant differences between the groups except that the need for retreatment was significantly higher in the large prostate group.</p> Conclusion <p>Rezūm therapy offers a safe and effective treatment option for both small and large prostates with sustained improvement over four years. However, patients with large prostates exhibited a higher retreatment rate (15.2%).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A comparative analysis of the outcomes of Rezūm therapy based on prostate size: a four-year retrospective analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月17日

查看全文
  • Mohamed Samir,
  • Mahmoud Ahmed Mahmoud,
  • Hossam Abdelsamie Abdelmonem,
  • Mohamed Elrefaie,
  • Khaled Abdelsattar Gad

摘要

Objective

To assess the safety and efficacy of Rezūm therapy in small versus large prostates through a four-year follow-up.

Patients and methods

One-hundred seventy patients who underwent Rezūm therapy were retrospectively included and divided into 2 equal groups, small (˂ 80gm) and large prostate groups (80-120 gm). Both groups were assessed preoperatively and at 3, 12, 24, 36, and 48 months post-procedure for operative time, number of vapor injection, catheterization time, hospital stay and post-procedure: prostatic size, prostate-specific antigen (PSA), post-void residual (PVR), maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), quality of life (QoL), International Index of Erectile Function (IIEF) and complications.

Results

The number of vapor injections was significantly higher in the large prostate group compared to the small prostate group (p < 0.001). Operative time and catheter duration were significantly longer in the large prostate group (p < 0.001), while hospital stay was similar between groups (p = 0.407). At 48 months post-Rezūm, both groups demonstrated statistically significant improvement in all measured outcomes (Qmax, IPSS, PVR, QoL, PSA, IIEF, and prostate size) (p < 0.05). Regarding postoperative complications, there were no significant differences between the groups except that the need for retreatment was significantly higher in the large prostate group.

Conclusion

Rezūm therapy offers a safe and effective treatment option for both small and large prostates with sustained improvement over four years. However, patients with large prostates exhibited a higher retreatment rate (15.2%).